Click for a HEPATIQ free trial

Hepatiq, Inc.

Creator of HEPATIQ® -The Ultimate Liver Test®

Download Company Flyer

PROBLEM & Solution

• Hospitals spend $12 billion annually worldwide on liver tests that provide modest predictive value. HEPATIQ improves outcome prediction by quantifying liver functional reserve. Blood tests, elastography and biopsy assess liver fibrosis or scarring. These tests miss the liver’s ability to compensate for fibrosis by regenerating and increasing blood flow. By quantifying remaining functional capacity, HEPATIQ assesses true disease stage. To use a car analogy, other tests estimate the air in the gas tank. HEPATIQ measures the gas in the gas tank. HEPATIQ is the only FDA cleared product on the market that quantifies remaining liver function.

HEPATIQ uses new patented software to analyze liver SPECT images and provide six indices of liver disease from a single 20 minute scan: quantitative liver function, steatosis/steatohepatitis, portal hypertension, alcoholic hepatitis, fibrosis stage and variceal size. It also provides a liver physiologic stage: H0 (normal) to H5 (transplant candidate). When fibrosis based tests reach the “what now?” point, turn to HEPATIQ for more insight.

DIAGNOSIS & THERAPY

Hepatologists, gastroenterologists and internists manage liver disease using fibrosis stage: F0 (normal) to F4 (cirrhosis), which provides a partial view. An F4 or F3 patient may be H0 or H1 and may remain stable for years. On the other hand, another F4 or F3 patient may be H2 or H3 and at risk of liver decompensation. Use HEPATIQ to determine the liver’s physiologic stage and get quantitative information on compensation status and prognosis.

Oncologists, interventionists and surgeons treat liver cancer to improve survival. Patients with compensated cirrhosis and large liver functional reserve can receive the most radical treatment. More individualized assessment is needed for patients with poorer functional reserve. Use HEPATIQ to assess liver functional reserve before an intervention or surgery.

RESEARCH

There are 28 publications on HEPATIQ. The HEPATIQ indices, PHM and fSV, were proven to predict outcomes in the prospective 8-year multi-center HALT-C trial and outperformed blood tests and biopsies. Patients with PHM<95 (H2 to H5) had a 15-fold increase in risk of adverse outcomes.

INTELLECTUAL PROPERTY

HEPATIQ is covered by six USA patents and five foreign patents. It has multiple trademarks. The company is also developing two new products HEPAPLAN™ and PANCREATIQ™ in collaboration with leading universities.

MARKET & CUSTOMERS

Chronic liver disease affects about 1 billion people worldwide. About 32,000 people die each year from it in the USA. The liver diagnostics market is $12 billion/year globally and growing 12% annually. Potential customers for HEPATIQ are about 30,000 hospitals and imaging centers worldwide.

Nuclear medicine physicians and radiologists use HEPATIQ to provide better diagnostics to referring clinical physicians while boosting hospital revenues. HEPATIQ is pure software and uses existing equipment and radioisotope. No capital investment is needed. The scan is reimbursed by insurance under CPT 78803. Medicare pays about $1,400 per scan (private insurance more). We charge the hospital $95 out of that for the HEPATIQ report.

TURNING POINT

Originally only blood tests and biopsies were available. Elastography first appeared in 2003 and has since become ubiquitous. But, given the limitations of fibrosis measurements, and quantitative liver function now available with HEPATIQ, we are at a turning point in liver disease management.

TEAM

Dipu Ghosh, MS, MBA. Chief Executive Officer

Marcela Pan, MA.Marketing Manager

Heather Hoefs, MA.Medical Education

Jorge LopezSales Rep – Miami

Chris HuntSales Rep – Houston

Scott Peairs Sales Rep – Denver

Paul Intagliata, BS. CME Software Manager

Ross Abedi, B.Sc.Software Engineer

Anjali Ghosh, B.Sc.Informatics

MEDICAL ADVISORY BOARD

Dr. (Prof.) Ashish Kumar, MD, DM, FRCP Consultant of Gastroenterology & HepatologySir Ganga Ram Hospital

Dr. Akshat Jain, MD, MPH Assistant Professor, Pediatrics, Hematology/Oncology Loma Linda University School of Medicine

Seth Lirette, PhD, Biostatistics and Radiation Oncology University of Mississippi Medical Center

Dr. Ethel Belho Sr. Consultant, Nuclear Medicine & PET Sir Ganga Ram Hospital

INVESTORS & PARTNERS

• To learn more about Hepatiq Inc., please visit us at the following investor conferences:

• MedInvest MedTech, AI & Digital Health Conference, Jun 3-4, San Francisco.
• Digital Venture Forum, July 7-11, Online.
• New York Venture Summit, September 9-10, New York.
• The MedTech Conference, October 5-8, San Diego.

Our goal is to make liver diagnosis and prognosis better for the one billion plus people worldwide who have various forms of liver disease. Below is a chart of some of the players in this market prepared by 360iResearch - a third-party market intelligence firm. Hepatiq Inc. (shown with a green oval) is well positioned in the "Vital" quadrant. To learn more about how you can help make a real difference, please email investors@hepatiq.com.

EMPLOYMENT

To apply for a job at Hepatiq, Inc., please send resume and salary expections to staffing@hepatiq.com. We are actively looking to add to our sales staff. Open positions are listed below. Click the position title to download the job description.

Director of Sales, Quantitative Liver Imaging

LOCATION

Hepatiq, Inc. 1200 Main Street, Suite B Irvine, CA 92614, USA. www.hepatiq.com sales@hepatiq.com

BACK

NEXT